|
Characteristic
|
Mean values, unless specified differently (range)
|
|---|
|
Age (years)
|
62 (28–87)
|
|
Primary site (#)
|
14 (50%) lung
|
|
9 (32%) breast
|
|
2 (7%) esophagus
|
|
1 (4%) lymphoma
|
|
2 (7%) other
|
|
Gender (#)
|
14 (50%) male
|
|
14 (50%) female
|
|
Time to CMR (months)
|
46.4 (1.7–344.5)
|
|
Smoking History (#)
|
16 (57%) yes
|
|
12 (43%) no
|
|
Hypertension (#)
|
16 (57%) yes
|
|
12 (43%) no
|
|
Body Mass Index (kg/m2)
|
27.7 (16.0–50.6)
|
|
Radiotherapy technique (#)
|
15 (54%) 3D conformal
|
|
11 (39%) IMRT
|
|
2 (7%) SBRT
|
|
Total radiotherapy courses (#)
|
23 (82%) one course
|
|
4 (14%) two courses
|
|
1 (4%) three courses
|
|
Chemotherapy (#)
|
13 (43%) concurrent
|
|
9 (32%) neoadjuvant/adjuvant
|
|
7 (25%) none
|
|
Adriamycin use (#)
|
7 (25%) yes
|
|
21 (75%) no
|
- CMR cardiac magnetic resonance imaging, 3D 3D conformal therapy, EQD2 equivalent dose in 2Gy fractions, IMRT intensity modulated radiation therapy, SBRT stereotactic body radiation therapy, V5Gy percentage volume of heart receiving at least 5Gy, # number of patients
